Reblozyl®▼ is reimbursed in Belgium as of August 1st 2021 for the
treatment of adult
patients:
- with transfusion-dependent anemia due to very low, low or intermediate-risk (IPSS-R)
myelodysplastic
syndrome (MDS) with ring sideroblasts, who had an unsatisfactory
response to or are ineligible to
erythropoietin-based therapy
- with transfusion-dependent anemia associated with β-thalassemia.
The maximum reimbursed posology is 1,75 mg/kg every 21 days for MDS and 1,25mg/kg
every 21 days for
beta-thalassemia.
Reblozyl®▼ treatment will stop being reimbursed if:
- there is no reduction of the transfusion burden after 9 weeks (3 cycles) at the
maximum dose level,
if the lack of response cannot be explained
otherwise (bleeding, surgical intervention, other
concomitant disease) or,
- anytime in case of unacceptable toxicities.4
▼This medicinal product is subject to additional monitoring. This will allow quick
Identification of new
safety information. Healthcare professionals are asked to report any
suspected adverse reactions. Before
prescribing Reblozyl®▼, please refer to the SmPC.
View the Eu SmPC in French, SmPC in Dutch.